Updated overall survival (OS) results of randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Hidenori Ibata
No relevant relationships to disclose
Masahiko Ando
No relevant relationships to disclose
Kazuhiro Asami
No relevant relationships to disclose
Yoshio Okano
No relevant relationships to disclose
Masaaki Fukuda
Stock Ownership - Stock Ownership
Hideyuki Nakagawa
No relevant relationships to disclose
Toshiyuki Kozuki
Honoraria - Chugai Pharma
Tateo Endo
No relevant relationships to disclose
Atsuhisa Tamura
No relevant relationships to disclose
Mitsuhiro Kamimura
Research Funding - Chugai Pharma
Kazuhiro Sakamoto
No relevant relationships to disclose
Michihiro Yoshimi
No relevant relationships to disclose
Yoshifumi Soejima
No relevant relationships to disclose
Yoshio Tomizawa
No relevant relationships to disclose
Shun-ichi Isa
No relevant relationships to disclose
Minoru Takada
No relevant relationships to disclose
Hideo Saka
No relevant relationships to disclose
Akihito Kubo
No relevant relationships to disclose
Tomoya Kawaguchi
No relevant relationships to disclose